Introduction
The spindle assembly checkpoint (SAC) is responsible to delaying chromosome segregation until all duplicated sister chromatids are bound and bi-oriented in the mitotic spindle. When this occurs, APC/C Cdc20 -mediated degradation of securin (PTTG1 in humans) and cyclin B1 takes place, and cells enter anaphase (1) reported PTTG1 overexpression in different tumor types (10) (11) (12) (13) (14) (15) (16) (17) (18) . PTTG1 is involved in several cellular processes including DNA damage repair, apoptosis, and angiogenesis. It also interacts with a number of factors both in vivo and in vitro. PTTG1 also possesses transactivating activity, inducing the upregulation of several other genes (19) .
Regarding PTTG1 function as a cell cycle regulator, during most of cell cycle PTTG1 is bound to a protease called separase and thus inhibits its proteolytic activity (20) . In metaphase, replicated sister chromatids are held together by the cohesin complex, an essential process to prevent premature separation of chromatids (21) . During metaphase to anaphase transition, once chromosomes are properly oriented, PTTG1 is degraded via APC/C Cdc20 . PTTG1 destruction releases separase inhibition, which in turn mediates degradation of the cohesin complex and sister chromatids separation proceed (10) .
PTTG1 function in apoptosis is currently under debate. In fact, it has been reported that PTTG1 overexpression promotes and inhibits apoptosis (10) . Thus, we sought to investigate the influence of PTTG1 protein on cell cycle and apoptosis induction in two prostate cancer cell lines that respond differentially to paclitaxel.
Materials and methods

Cell culture
Human prostate cancer PC3 and LNCaP cell lines were obtained from the Interlab Cell Line Collection (Genoa, Italy). No further authentication was made by the authors. All the experiments were done using vials from the first ten passages after receipt. Paclitaxel-resistant PC3 cell line (PC3 PTXR) was generated in our laboratory.
Parental PC3 cells were treated with 1 μM paclitaxel for three days; then, the drug was withdrawn from the medium and surviving cells were allowed to grow. These cells were 6 again subjected to the same treatment and the resulting paclitaxel-resistant cells were used for the assays. Cell lines were routinely grown in RPMI 1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 10 mM HEPES buffer and 1 mM glutamine in a 37 o C, humidified incubator under 5% CO 2 . Cells were harvested by trypsinization. The stock solution of paclitaxel (Calbiochem, San Diego, CA) was prepared at 10 mM in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO) and stored frozen. In all the experiments, DMSO was added to untreated cells.
Small interfering RNA
Small interfering RNA (siRNA) transfections were carried out using the Dharmafect 2 reagent (Thermo Fisher Dharmacon, Lafayette, CO) according to the manufacturer's instructions. The PTTG1 and Mcl-1-specific siRNAs and the control negative siRNA were validated pools from Thermo Fisher Dharmacon (On-Target plus Smart pools L-004308, L-004501, and D-001810). All siRNAs were used at 100 nM.
Cells were subjected to different treatments 24 h after silencing.
Plasmid transfections
Cells were transiently transfected with a plasmid carrying a non degradable 
Antibodies
Rabbit polyclonal anti-Bax and anti-Bak were available from BD Biosciences (San Jose, CA). Mouse monoclonal anti-Bcl-xL, rabbit polyclonal anti-Mcl-1, anti-cyclin B1 and anti-phospho-histone H3 (Ser10) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); mouse monoclonal anti-β-actin from Sigma. Rabbit polyclonal anticleaved caspase 9 (Asp 315) was from Cell Signaling (Danvers, MA). Rabbit antiBubR1 antibody was from Bethyl Laboratories (Montgomery, TX). Rabbit polyclonal anti-PTTG1 was previously described (23) . Dilutions used in Western blots were antiBax (1:1,000); anti-Bak (1:3,000); anti-Bcl-xL (1:100); anti-Mcl-1 (1:1,000); anti-cyclin B1 (1:1,000); anti-phospho-histone H3 (1:500); anti-β-actin (1:16,000); anti-cleaved caspase 9 (1:500); anti-BubR1 (1:3,000) and anti-PTTG1 (1:1,000). Caspase-mediated cleavage of poly-(ADP-ribose) polymerase (PARP) was assessed by Western blot using a mouse monoclonal anti-human PARP (BD Biosciences) at 1:250 dilution.
Western blotting
Cells were lysed in Nonidet P-40 (NP40) lysis buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol and 1% NP40). Equal amounts of total protein, as determined by using BCA protein assay (Pierce, Rockford, IL), were separated by SDS-PAGE on 4-20% gradient polyacrylamide gels (Invitrogen, Carlsbad, CA). Gels were electroblotted onto nitrocellulose membranes (GE Healthcare, Little Chalfont, UK).
Membranes were stained with Ponceau S to ensure that protein amounts were comparable. For immunodetection, blots were blocked in 1% blocking reagent (Roche, 
Statistical analysis
Data comparing differences between two conditions were statistically analyzed, when indicated, using paired Student's t test. Differences were considered significant when P < 0 .05. Calculations were performed using Prism 4.0 (GraphPad, San Diego, CA). (Fig. 1 ). These data suggest that PC3 cells were reaching mitosis and subsequently undergoing slippage, whereas LNCaP cells were also reaching mitosis but remained fully blocked in this phase.
Results
Paclitaxel-treated LNCaP cells undergo apoptosis during mitosis but less sensitive
PC3 cells mostly die after slippage
Several proteins belonging to the Bcl-2 family were also examined. As previously described (2) (Fig. 2C) . Finally, to check that there were not any ploidy changes provided that cells were either in mitosis or not reaching mitosis, a FISH was carried out. As observed in Fig. 2D the percentage of cells with higher ploidy than the normal was low and similar in both 48 h paclitaxel-treated siRNA control and siRNA PTTG1 cells, supporting western blot and cell cycle data. Representative FISH images are shown in Supplementary Fig. S1A .
PTTG1 overexpression increases paclitaxel-induced mitotic arrest of LNCaP cells with a concomitant increase in apoptosis
To further investigate the role of PTTG1 in the response to paclitaxel, LNCaP cells were transiently transfected with a non-degradable PTTG1 mutant and treated with 2.5 M paclitaxel during 48 h. PARP cleavage and caspase 9 activation were higher in paclitaxel-treated PTTG1-transfected cells as compared with treated cells transfected with empty vector (Fig. 3A) . The annexin V binding experiment also confirmed these results (Fig. 3B) . In relation to the effect on cell cycle, phosphorylated histone H3, BubR1 and cyclin B1 were increased in PTTG1-transfected LNCaP cells after paclitaxel (Fig. 3A) . FISH results also confirmed that cells were not slipping out the mitotic arrest imposed by paclitaxel ( Fig. 3C and Supplementary Fig. S1B ).
PTTG1 gene silencing diminishes paclitaxel-induced apoptosis by inhibiting mitotic slippage in PC3 cells
The same experimental approach used above was extended to PC3 cells. As observed by the 85 kDa band of PARP protein, caspase 9 activation (Fig. 4A ) and annexin V binding experiment (Fig. 4B) , PTTG1 silencing diminishes the apoptotic sensitivity of PC3 cells to paclitaxel treatment. Both siRNA control and PTTG1-silenced PC3 cells showed increased levels of phosphorylated histone H3 and cyclin B1 after 24 h of paclitaxel treatment, whereas BubR1 levels remained similar to DMSOtreated siRNA control and PTTG1-silenced cells. As compared with 24 h, paclitaxel treatment during 48 h induces a decrease in phosphorylated histone H3, BubR1 and cyclin B1 levels in siRNA control cells that were much less obvious in PTTG1-silenced cells (Fig. 4A) . Mcl-1 L levels diminished after paclitaxel treatment in all conditions, but more markedly at 48 h. Bcl-xL remained higher in 24 h paclitaxel-treated cells silenced for PTTG1 in relation to siRNA control cells treated in the same way. We did not detect any appreciable changes in Bax and Bak proteins (Fig. 4A) . Cell cycle was also examined to further elucidate the effect of PTTG1 silencing on this cell line. DMSOtreated PTTG1-silenced cells showed an increase in G 1 phase and a decrease in S phase, as compared with DMSO-treated siRNA control cells (Fig. 4C) 
slightly higher than in paclitaxel-treated siRNA control cells (Fig. 4C) . As both paclitaxel-treated siRNA control and PTTG1-silenced cells peak in a DNA content corresponding to G 2 /M phases and, provided that mitotic and slipped cells are undistinguishable by this technique, FISH was performed. Representative photographs are shown in Supplementary Fig. S1C . 48 h paclitaxel-treated siRNA control cells show 71.6% of cells with higher ploidy than the normal, whereas paclitaxel-treated PTTG1-silenced cells show a reduction of 26.3% in such percentage (Fig. 4D) . Altogether, these data point to an inhibition of slippage upon PTTG1 silencing.
PTTG1 overexpression increases paclitaxel-induced mitotic arrest of PC3 cells but diminishes the apoptotic effect of the drug
PC3 cells were also transiently transfected with the PTTG1 mutant and treated with 2.5 M paclitaxel during 48 h. Paclitaxel-treated PTTG1-transfected PC3 cells were more blocked in mitosis than treated cells transfected with empty vector, as observed by increased levels of phosphorylated histone H3, BubR1 and cyclin B1, but, as in the case of PTTG1 silencing, this event was associated with diminished PARP cleavage, caspase 9 activation and with a reduced percentage of apoptotic cells; this is, with a minor induction of apoptosis ( Fig. 5A and B) . Bcl-xL, Bax and Bak levels remain essentially unchanged, whereas Mcl-1 L levels were higher in paclitaxel-treated percentage, indicating an inhibition of slippage in the last condition ( Fig. 5C and Supplementary Fig. S1D ).
Simultaneous PTTG1 and Mcl-1 downregulation has a pro-apoptotic effect on PC3 cells during mitosis
As results obtained in PC3 cells indicate that the increase in mitotic cells achieved with paclitaxel in both PTTG1-silenced and transfected cells not only does not increase apoptosis but diminishes it, we reasoned that apoptosis only can be triggered post-slippage or that other blockades might exist that prevent apoptosis during mitosis.
To test this hypothesis, we focused on Mcl-1 because of its elevated level during the moment of maximum mitosis in this cell line; this is, after 24 h of paclitaxel treatment. (Fig. 7A) , supporting the role of Mcl-1 L protein in the inhibition of apoptosis during mitosis. As western blot data suggested a stronger paclitaxel-induced mitotic arrest in the resistant cells as compared with the parental ones, we studied cell cycle and ploidy in this context. Cycle profiles were similar in both cell lines (Fig. 7C) , however, FISH results showed a 66.7% of paclitaxel-treated PC3 cells with higher ploidy than the normal, whereas in paclitaxeltreated PC3 PTXR cells this percentage was 54.3%, corroborating the diminished slippage in PC3 PTXR cells upon paclitaxel treatment (Fig. 7D and Supplementary Fig.   S1E ). 
Discussion
Defects in cell cycle and apoptosis machineries influence cell responses to chemotherapeutic drugs, thus elucidating the mechanisms underlying bad or incomplete responses could help to improve therapy regimens. Paclitaxel and its semi-synthetic analogue, docetaxel, are currently being used to induce regression in hormonerefractory prostate cancers after androgen deprivation therapy failure (24) , this is, first line treatment for hormone-refractory prostate cancers is mainly taxane-based chemotherapy (24, 25) . As it has been reported (26), PC3 and LNCaP cells show a different apoptotic response after paclitaxel treatment. It has also been described that PC3 cells treated with 50 ng/ml of paclitaxel during 24 h and then withdrawn, exit from mitosis without cytokinesis, leading to the appearance of polyploid cells. In this context, cell death was a slow and delayed process (a sub-G 1 population appeared after 72 h of treatment), occurring after DNA endoreduplication (27) . Also, PC3 cells have been shown to exit from mitosis after a prolonged mitotic arrest induced by 150 nmol/L paclitaxel, and remained in an abnormal G 1 -like state for extended period of time (28) .
Within our experimental conditions, we have observed that most PC3 cells had reached mitosis but were not in apoptosis after 24 h of 2.5 M paclitaxel treatment; similarly treated LNCaP cells were also in mitosis but initiating apoptosis. After 48 h of drug treatment, most PC3 cells have exited from mitosis by slippage, with a concomitant increase in apoptosis. Apoptosis in LNCaP cells were also increased at that time, surpassing the apoptotic induction observed in PC3 cells, but this was associated with an increase in mitotic cells. Apoptosis induction by paclitaxel is related to its ability to arrest cells in mitosis (28) ; our data also suggest that LNCaP, the cell line capable of maintaining a more efficient mitotic arrest, is more sensitive to the apoptotic effect of paclitaxel than slippage-prone PC3 cell line. 
There are several reports addressing PTTG1 functions in apoptosis. Concretely, PTTG1 overexpression may cause both p53-dependent and p53-independent apoptosis in MCF7 breast cancer cells (p53 wild type) and MG63 osteosarcoma cells (p53 deficient) (29) . It also has been published that PTTG1 induces p53 promoter activation through c-myc and that PTTG1 overexpression stimulates Bax expression, a known downstream target of p53 (30) . By contrary, it has been described that PTTG1 interacts with p53 in vitro and in vivo, and that such interaction blocks the specific binding of p53 to DNA, inhibiting its transcriptional activity. In this context, Bax promoter activity decreases due to PTTG1-p53 interaction, leading to diminished apoptosis (31) . It also has been observed in hepatoma cell lines that PTTG1 overexpression attenuates p53 induced apoptosis (32) . Specifically in prostate cancer, it has been observed that LNCaP In the context of apoptosis induction by an antimitotic drug such as paclitaxel, we have identified two situations in which PTTG1 influences cell fate differentially.
PTTG1 silencing in PC3 cells does not affect their ability to reach mitosis in response to paclitaxel treatment, moreover, the maintenance of the mitotic state is strengthened; similarly, paclitaxel-treated, PTTG1 overexpressing PC3 cells also showed an increased maintenance of mitosis. Both PTTG1 overexpression and silencing lead to increased SAC activation after paclitaxel treatment, as indicate elevated BubR1 levels; this could explain the increase in mitotic cells achieved after paclitaxel treatment. The most striking and paradoxical effect observed in both situations is that the increase in mitosis, 
